Lupin has reported results for third quarter ended December 31, 2012.
The company has posted over 2-fold rise in its net profit at Rs 448.30 crore for the quarter as compared to Rs 214.61 crore for the same quarter in the previous year. Total income of the company has increased by 42.36% at Rs 2002.77 crore for quarter under review as compared to Rs 1406.85 crore for the quarter ended December 31, 2011.
On consolidated basis, the company has reported 42.61% rise in its net profit at Rs 335.23 crore for the quarter ended December 31, 2012 as compared to Rs 235.06 crore for the same quarter in the previous year. Total income of the company has increased by 38.71% at Rs 2527.57 crore for quarter under review as compared to Rs 1822.24 crore for the quarter ended December 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1915.10 |
| Dr. Reddys Labs. | 1367.40 |
| Cipla | 1464.20 |
| Zydus Lifesciences | 1156.80 |
| Lupin | 2493.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: